Cargando…

Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer

BACKGROUND: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known about influences of current regimens on circulating lymphocyte levels and phenotypes. Similarly, clinico-pathological factors that modify these influences, and implications for future immune health rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Rashmi, Foster, Ruth E., Horgan, Kieran, Mounsey, Katherine, Nixon, Helen, Smalle, Natuley, Hughes, Thomas A., Carter, Clive RD.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727393/
https://www.ncbi.nlm.nih.gov/pubmed/26810608
http://dx.doi.org/10.1186/s13058-015-0669-x
_version_ 1782411957051064320
author Verma, Rashmi
Foster, Ruth E.
Horgan, Kieran
Mounsey, Katherine
Nixon, Helen
Smalle, Natuley
Hughes, Thomas A.
Carter, Clive RD.
author_facet Verma, Rashmi
Foster, Ruth E.
Horgan, Kieran
Mounsey, Katherine
Nixon, Helen
Smalle, Natuley
Hughes, Thomas A.
Carter, Clive RD.
author_sort Verma, Rashmi
collection PubMed
description BACKGROUND: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known about influences of current regimens on circulating lymphocyte levels and phenotypes. Similarly, clinico-pathological factors that modify these influences, and implications for future immune health remain mainly unexplored. METHODS: We used flow-cytometry to assess circulating lymphocyte levels and phenotypes in 88 primary breast cancer patients before chemotherapy and at time-points from 2 weeks to 9 months after chemotherapy completion. We examined circulating titres of antibodies against pneumococcal and tetanus antigens using ELISAs. RESULTS: Levels of B, T and NK cells were significantly reduced 2 weeks after chemotherapy (p < 0.001). B cells demonstrated particularly dramatic depletion, falling to 5.4 % of pre-chemotherapy levels. Levels of all cells recovered to some extent, although B and CD4(+) T cells remained significantly depleted even 9 months post-chemotherapy (p < 0.001). Phenotypes of repopulating B and CD4(+) T cells were significantly different from, and showed no sign of returning to pre-chemotherapy profiles. Repopulating B cells were highly depleted in memory cells, with proportions of memory cells falling from 38 % to 10 % (p < 0.001). Conversely, repopulating CD4(+) T cells were enriched in memory cells, which increased from 63 % to 75 % (p < 0.001). Differences in chemotherapy regimen and patient smoking were associated with significant differences in depletion extent or repopulation dynamics. Titres of anti-pneumococcal and anti-tetanus antibodies were both significantly reduced post-chemotherapy and did not recover during the study (p < 0.001). CONCLUSION: Breast cancer chemotherapy is associated with long-term changes in immune parameters that should be considered during clinical management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0669-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4727393
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47273932016-01-27 Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer Verma, Rashmi Foster, Ruth E. Horgan, Kieran Mounsey, Katherine Nixon, Helen Smalle, Natuley Hughes, Thomas A. Carter, Clive RD. Breast Cancer Res Research Article BACKGROUND: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known about influences of current regimens on circulating lymphocyte levels and phenotypes. Similarly, clinico-pathological factors that modify these influences, and implications for future immune health remain mainly unexplored. METHODS: We used flow-cytometry to assess circulating lymphocyte levels and phenotypes in 88 primary breast cancer patients before chemotherapy and at time-points from 2 weeks to 9 months after chemotherapy completion. We examined circulating titres of antibodies against pneumococcal and tetanus antigens using ELISAs. RESULTS: Levels of B, T and NK cells were significantly reduced 2 weeks after chemotherapy (p < 0.001). B cells demonstrated particularly dramatic depletion, falling to 5.4 % of pre-chemotherapy levels. Levels of all cells recovered to some extent, although B and CD4(+) T cells remained significantly depleted even 9 months post-chemotherapy (p < 0.001). Phenotypes of repopulating B and CD4(+) T cells were significantly different from, and showed no sign of returning to pre-chemotherapy profiles. Repopulating B cells were highly depleted in memory cells, with proportions of memory cells falling from 38 % to 10 % (p < 0.001). Conversely, repopulating CD4(+) T cells were enriched in memory cells, which increased from 63 % to 75 % (p < 0.001). Differences in chemotherapy regimen and patient smoking were associated with significant differences in depletion extent or repopulation dynamics. Titres of anti-pneumococcal and anti-tetanus antibodies were both significantly reduced post-chemotherapy and did not recover during the study (p < 0.001). CONCLUSION: Breast cancer chemotherapy is associated with long-term changes in immune parameters that should be considered during clinical management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0669-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-26 2016 /pmc/articles/PMC4727393/ /pubmed/26810608 http://dx.doi.org/10.1186/s13058-015-0669-x Text en © Verma et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Verma, Rashmi
Foster, Ruth E.
Horgan, Kieran
Mounsey, Katherine
Nixon, Helen
Smalle, Natuley
Hughes, Thomas A.
Carter, Clive RD.
Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
title Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
title_full Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
title_fullStr Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
title_full_unstemmed Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
title_short Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
title_sort lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727393/
https://www.ncbi.nlm.nih.gov/pubmed/26810608
http://dx.doi.org/10.1186/s13058-015-0669-x
work_keys_str_mv AT vermarashmi lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer
AT fosterruthe lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer
AT horgankieran lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer
AT mounseykatherine lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer
AT nixonhelen lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer
AT smallenatuley lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer
AT hughesthomasa lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer
AT cartercliverd lymphocytedepletionandrepopulationafterchemotherapyforprimarybreastcancer